> Details

Grela-Wojewoda, Aleksandra; Püsküllüoğlu, Mirosława; Sas-Korczyńska, Beata; Zemełka, Tomasz; Pacholczak-Madej, Renata; Wysocki, Wojciech M.; Wojewoda, Tomasz; Adamczyk, Agnieszka; Lompart, Joanna; Korman, Michał; Mucha-Małecka, Anna; Ziobro, Marek; Konduracka, Ewa

Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2- Positive Breast Cancer Patient Population

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2- Positive Breast Cancer Patient Population
  • Contributor: Grela-Wojewoda, Aleksandra; Püsküllüoğlu, Mirosława; Sas-Korczyńska, Beata; Zemełka, Tomasz; Pacholczak-Madej, Renata; Wysocki, Wojciech M.; Wojewoda, Tomasz; Adamczyk, Agnieszka; Lompart, Joanna; Korman, Michał; Mucha-Małecka, Anna; Ziobro, Marek; Konduracka, Ewa
  • Published: MDPI AG, 2022
  • Published in: Cancers, 14 (2022) 14, Seite 3353
  • Language: English
  • DOI: 10.3390/cancers14143353
  • ISSN: 2072-6694
  • Origination:
  • Footnote:
  • Description: Trastuzumab-induced cardiotoxicity (TIC) can lead to early treatment discontinuation. The aim of this study was to evaluate: N-terminal brain natriuretic peptide (NT-proBNP), creatine kinase-MB (CK-MB), myoglobin, and selected biochemical and clinical factors as predictors of TIC. One hundred and thirty patients with HER2-positive BC receiving adjuvant trastuzumab therapy (TT) were enrolled. Measurement of cardiac markers and biochemical tests as well as echocardiography were performed prior to TT initiation and every three months thereafter. Cardiotoxicity leading to treatment interruption occurred in 24 patients (18.5%). While cardiotoxicity caused early treatment discontinuation in 14 patients (10.8%), the TIC resolved in 10 (7.7%) and TT was resumed. The most common complication was a decrease in left ventricular ejection fraction of more than 10% from baseline or below 50% (7.7%). In patients with TIC, there was no increase in the levels of NT-proBNP, myoglobin, and CK-MB. BMI, hypertension, ischemic heart disease, diabetes, age, cancer stage, type of surgery, use of radiotherapy, chemotherapy, and hormone therapy were shown to not have an effect on TIC occurrence. NT-proBNP, myoglobin, and CK-MB are not predictors of TIC. There is an ongoing need to identify biomarkers for TIC.
  • Access State: Open Access